Genfit S.A. (NASDAQ:GNFT) Sees Significant Increase in Short Interest

Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 67,800 shares, a growth of 16.5% from the September 15th total of 58,200 shares. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is presently 6.3 days. Approximately 0.1% of the shares of the company are short sold.

Genfit Price Performance

GNFT traded up $0.37 on Wednesday, hitting $6.28. The company's stock had a trading volume of 35,695 shares, compared to its average volume of 17,429. Genfit has a 12 month low of $2.97 and a 12 month high of $6.29. The company's 50 day simple moving average is $4.66 and its 200-day simple moving average is $4.30. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and set a $13.00 target price on shares of Genfit in a research report on Friday, October 11th.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.